Zenas BioPharma, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Zenas BioPharma, Inc. (ZBIO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $8.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Zenas BioPharma, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $8.62M, a 42.58% increase year-over-year.
- Zenas BioPharma, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $9.20M, a 70.72% increase year-over-year.
- Zenas BioPharma, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $7.34M, a 158.04% increase year-over-year.
- Zenas BioPharma, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $6.04M, a 293.55% increase year-over-year.
- Zenas BioPharma, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $26.35M, a 143.48% increase from fiscal 2024.
- Zenas BioPharma, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $10.82M, a 209.61% increase from fiscal 2023.
- Zenas BioPharma, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.50M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.62M 10-Q · filed 2026-08-13 | $17.81M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $9.20M 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $26.35M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $7.34M 10-Q · filed 2025-11-12 | $13.38M derived: sum of 2 quarters · filed 2026-08-13 | $18.77M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $6.04M 10-Q · filed 2026-08-13 | $11.43M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $5.39M 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $10.82M 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $2.84M 10-Q · filed 2025-11-12 | $4.38M derived: sum of 2 quarters · filed 2025-11-12 | $5.33M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.54M 10-Q · filed 2025-11-12 | $2.48M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $947.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $3.50M 10-K · filed 2025-03-11 | |||
| 2023-09-30 | $1.00M 10-Q · filed 2024-11-12 | $1.67M derived: sum of 2 quarters · filed 2024-11-12 | $2.36M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $669.00K 10-Q · filed 2024-11-12 | $1.36M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $687.00K 10-Q · filed 2024-11-12 |